SCHEMBL4176368

SCHEMBL4176368

O=c1[nH]c(=O)n(C2CC(F)C(COC(c3ccccc3)(c3ccccc3)c3ccccc3)O2)cc1C(I)=CI

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TYMP P19971 1/20 0.43
HSP90AA1 P07900 1/20 0.42
TYMS P04818 4/20 0.40
RNASE1 P07998 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
TK1 P04183 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
DUT P33316 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213020 1.00 TYMP (0.43) TYMPHSP90AA1TYMSRNASE1CYP1A2
SCHEMBL3065197 0.82 TK1 (0.47) HSP90AA1TK1
SCHEMBL3065199 0.82 TK1 (0.47) HSP90AA1TK1
SCHEMBL4170033 0.81 TK1 (0.52) CYP1A2CYP3A4TSHRTK1BLM
SCHEMBL4170030 0.81 TK1 (0.52) CYP1A2CYP3A4TSHRTK1BLM
SCHEMBL4170246 0.81 HSP90AA1 (0.45) TYMPHSP90AA1TYMSRNASE1TK1
SCHEMBL4173870 0.81 HSP90AA1 (0.43) TYMPHSP90AA1TYMSRNASE1DUT
SCHEMBL3571173 0.78 DUT (0.57) TYMPHSP90AA1TYMSDUT
SCHEMBL13444847 0.78 DUT (0.57) TYMPHSP90AA1TYMSDUT
SCHEMBL3571174 0.78 DUT (0.57) TYMPHSP90AA1TYMSDUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090004137-A1 Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) 2009-01-01 US disclosed
EP-1827457-A1 URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2007-09-05 EP disclosed
WO-2006067606-A1 URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2006-06-29 WO disclosed
EP-1674104-A1 Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2006-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090004137-A1 Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv NUDT1, UMPS, UPP1 TYMP 68/4885HSP90AA1 3549/4885TYMS 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.